iSTAR Medical Expands Commercial Deployment with First
For immediate release
iSTAR Medical Expands Commercial deployment with First MINIject® surgeries in Swiss
- The only commercially available MIGS device currently targeting the supraciliary space now available for patients and surgeons in Switzerland
- First locations interpreted by Teacher. Doctor Kaweh Mansouri to Visio Switzerland, Clinic of Montchoisi, Lausanne and teacher. Doctor med. Jan Darius Unterlauft at InselspitalBern
WAVRE, Belgium — ten May 2022: iSTAR Medical, a medical technology company providing breakthrough eye care solutions to patients, today announced the continued expansion of its commercial deployment for MINIject® to Switzerland. MINIject® is iSTAR Medical’s minimally invasive glaucoma surgery (MIGS) implant and currently the only commercially available supraciliary MIGS device. Swiss patients with open-angle glaucoma can now benefit from MINIject®which has demonstrated significant and sustained performance, combined with a favorable safety profile.
The first implants with MINIject® have now been successfully completed at Swiss Visio, Clinique de Montchoisi, Lausanne by Prof. Dr Kaweh Mansouri and Inselspital, Bern by Prof. Dr. med. Jan Darius Unterlauft. This follows the recent expansion of MINIject by iSTAR Medical® in the UK in March.
Glaucoma is the leading cause of irreversible blindness, affecting around 100 million people worldwide and around 10 million in Europe alone.1,2 MIGS represents the most promising and fastest growing treatment for glaucoma, due to its improved safety profile compared to traditional surgery.1
Teacher. Dr Kaweh Mansouriglaucoma specialist (Lausanne) commented: “Glaucoma is a growing problem in increasingly aging Swiss population, with the incidence of glaucoma rising from 2% of people above old 50 at 5-8% in people over 70. Access to MINIject will now allow me to offer a novel and a safe a bit intrusive surgical approach to my patients, postponing more invasive surgery and preserving vision longer.”
Teacher. Doctor med. Jan Darius Unterlauft (Bern) commented: “I am delighted to be able to offer MINIject for patients currently living with–angle glaucoma. This innovative MIGS device, with its distinctive STAR material, provides a clear thrive to my the patients for reachand the right balance of significant intraocular pressure reduction with favorable security, supported longer term.”
Michel Vanbrabant, CEO of iSTAR Medical, commented: “Following our recent expansion in the UK, our deployment in Switzerland further away executed our engagement provide patients and surgeons through Europe access to MINIject, currently the only commercially available MIGS device targeting the supraciliary space. With the timely addition of Switzerland, we are well on our way to preserving the vision of glaucoma patients across Europe.”
– Ends –
For more information
Marketing Manager, iSTAR Medical
[email protected]; +32 10 77 16 54
For the media
Consilium Strategic Communications
Amber Fennell, Chris Welsh, Kris Lam
About iSTAR Medical
iSTAR Medical is committed to providing breakthrough eye care solutions. Our most advanced product, MINIject®, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness – and we are aiming to gain market approval in the United States. We believe that MINIject®The distinctive tissue integration capabilities of provide a safer and more efficient option for patients. We are building an exceptional team and a pipeline of potentially leading products such as MINIject® establishing new treatment paradigms in eye care conditions with the highest patient needs. For more information, visit: www.istar-medical.com
MINIject® is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject® combines the distinctive porous structure of its exclusive STAR material with the power offered by the supraciliary space. As a result, it is designed to improve natural fluid flow, reduce intraocular pressure (IOP) and the need for medication, while integrating with surrounding tissues, limiting inflammation, fibrosis and subsequent complications.
Glaucoma is a progressive disease that affects more than 100 million people worldwide, of which primary open-angle glaucoma is the most common form.1,2 Reducing IOP, through medication or surgery, helps delay the progression of the disease.3 Medications are usually the first-line treatment, but adding more drops gradually can burden patients with side effects, compliance issues, and costs.1,3 Invasive surgery can present risks of irreversible complications and often requires long-term management of the patient.1,3 MIGS is the most promising and fastest growing treatment for glaucoma due to its improved safety profile.1 We believe that MINIject® could become a leading MIGS device with its promising long-term efficacy and safety.
1 Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021. https://www.market-scope.com/pages/reports/267/2021-glaucoma-surgical-device-market-report
2 Jonas JB, Aung T, Bourne RR et al. “Glaucoma”. Lancet 2017; 390: 2083–93
3 “European Glaucoma Society terminology and guidelines for glaucoma”, 4th edition: British Journal of Ophthalmology. 2017;101:1-195 https://bjo.bmj.com/content/101/5/73